Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Merck & Co, Inc.

Oncology Briefing®: Putting Evidence Into Practice—PARP Inhibition for DNA Repair-Deficient Prostate Cancer

Release Date: April 30, 2021
Expiration Date: April 30, 2022

Activity Overview

This online activity is designed to provide a concise and focused overview on an important clinical topic and includes information on the utility of PARP inhibitors in the management of metastatic castration-resistant prostate cancer. The engaging, multimedia format of this program includes audio commentary from an expert thought leader integrated with text-based elements.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Merck & Co, Inc.

 

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational program is directed toward medical oncologists, urologists, researchers, and investigators who treat or are interested in the treatment of prostate cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain the mechanistic rationale for investigating PARP inhibitors for the treatment of patients with mCRPC with DNA repair deficiencies
  • Describe the role of genomic testing for selecting patients with mCRPC for treatment with PARP inhibitors using biomarkers appropriately
  • Assess emerging data from clinical trials investigating PARP inhibitors to address unmet needs for patients with DNA repair-deficient mCRPC and how these data may impact current treatment paradigms
  • Discuss strategies to monitor for, identify, and mitigate the impact of treatment-related adverse events that may occur among patients with mCRPC receiving treatment with PARP inhibitors

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.

Faculty

Joseph W. Kim, MD
Joseph W. Kim, MD
Associate Professor
Medical Oncology
Yale School of Medicine
Yale Cancer Center
New Haven, CT

Disclosures: Consultant: Clovis Oncology

Oliver Sartor, MD
Oliver Sartor, MD
Laborde Professor for Cancer Research
Medical Director, Tulane Cancer Center
Associate Dean for Oncology
Tulane University School of Medicine
New Orleans, LA

Disclosures: Grant/Research/Support: Advanced Accelerator Applications, AstraZeneca, Bayer, Constellation Pharmaceuticals, Dendreon, Endocyte, lnvitae, Janssen, Merck, Progenies, Sanofi, SOTIO; Consultant: Advanced Accelerator Applications, Astellas, AstraZeneca, Bayer, Blue Earth Diagnostics, Nordic Pharma, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis Oncology, Constellation Pharmaceuticals, Dendreon, EMD Serono, ITM Isotopen Technologien Meunchen, Janssen, Myovant Sciences, Myriad Genetics, Noria Therapeutics, Novartis, Noxopharm, Biopharma, Pfizer, Sanofi, Teneobio, Telix Pharmaceuticals, Theragnostics

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
3031
Filter By